Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Hypertension (Dallas, Tex. : 1979)|March 11, 1991
Systolic Hypertension of the Elderly Program (SHEP). Part 10: AnalysisJ Wittes, B Davis, K Berge, et al.
Vaccine|December 2, 1999
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B virusesJ J Treanor, K Kotloff, R F Betts, et al.
Controlled Clinical Trials|October 1, 1993
Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP)B R Davis, J Wittes, S Pressel, et al.
Controlled Clinical Trials|April 1, 1992
Quality control of dietary data collection in the CARDIA studyJ E Hilner, A McDonald, L Van Horn, et al.
JAMA|July 20, 1999
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trialK L Nichol, P M Mendelman, K P Mallon, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 5, 1997
Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acidsB A Clevidence, J T Judd, E J Schaefer, et al.
Archives of Internal Medicine|October 10, 1994
Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly programW B Applegate, S Pressel, J Wittes, et al.
Lancet (London, England)|September 14, 1996
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial GroupF Nosten, C Luxemburger, D E Kyle, et al.
Controlled Clinical Trials|October 2, 2001
Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshopV G De Gruttola, P Clax, D L DeMets, et al.
The New England Journal of Medicine|August 7, 1999
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupH B Rubins, S J Robins, D Collins, et al.
Pageof 5